Market research
APEN Apollo Endosurgery Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 580M
- P/E ratio
- Not available
- Analyst target
- 10
- Dividend yield
- 0.0%
- Beta
- 2.32
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Healthcare Equipment & Supplies
- ISIN
- US03767D1081
- Market cap
- 580M
- P/E ratio
- Not available
- Analyst target
- 10
- Dividend yield
- 0.0%
- Beta
- 2.32
About
About Apollo Endosurgery Inc
Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices for gastrointestinal therapeutic endoscopy. The company offers OverStitch and OverStitch Sx Endoscopic Suturing Systems that enable advanced endoscopic procedures by allowing physicians to suture and secure the approximation of tissue through a flexible endoscope. It also provides Orbera, an intragastric balloon system that reduces stomach capacity causing patients to consume less following the procedure, and delays gastric content emptying, which assists the patient in losing weight under the Orbera Intragastric Balloon System, BIB, and Orbera365 Managed Weight Loss System brands. In addition, the company offers X-Tack Endoscopic HeliX Tacking System, a suture-based device for closing and healing defects in the lower and upper gastrointestinal tract. The company sells its products to medical service providers, hospitals, outpatient surgical centers, clinics, and physicians in the United States, Costa Rica, Australia, and other European countries. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the APEN discussion.
5 years, 4 months ago
Apollo Endosurgery, Inc is currently in a long term uptrend where the price is trading 61.1% above its 200 day moving average.
From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.9.
Apollo Endosurgery, Inc's total revenue rose by 7.3% to $13M since the same quarter in the previous year.
Its net income has increased by 51.3% to $-4M since the same quarter in the previous year.
Finally, its free cash flow grew by 59.0% to $-3M since the same quarter in the previous year.
Based on the above factors, Apollo Endosurgery, Inc gets an overall score of 5/5.